Diterpenoid of (9β-h)-pimarane parent nucleus having Anti-colon cancer activity and derivative thereof, and preparation method therefor
By isolating secoicacinlivitholide F and G from the leaves of I.oliviformis, the toxic side effects and drug resistance of existing colon cancer chemotherapy drugs were solved, effective inhibition of colon cancer cells was achieved, and low-toxic anti-cancer treatment options were provided. .
Patent Information
- Application Number
- PCT/CN2024/081800
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-28
AI Technical Summary
Existing colon cancer chemotherapy drugs such as 5-FU have strong toxic and side effects on patients and are prone to drug resistance, resulting in poor treatment effects, and lack of low-toxic anti-cancer drugs, which affects patients' quality of life.
Two new skeleton compounds of secoicacin-livitholide F and secoicacin-livitholide G from the dried leaves of I.oliviformis plants were isolated from the dried leaves of I.oliviformis plants, secoicacin-livitholide G, and their extraction methods were prepared. The colon was found through activity evaluation. Cancer cells have significant inhibitory effects, especially secoicacinlivitholide G has a stronger inhibitory effect on HT-29 and SW620 cell lines than 5-FU.
The inhibitory effect of compound secoicacinlivitholide G on colon cancer cells is about 3 times that of 5-FU, and has the potential to be a leading compound for anti-colon cancer drugs, providing a new low-toxic anti-cancer treatment regimen.
Smart Images

Figure CN2024081800_28112024_PF_FP_ABST
Abstract
Description
Diterpenoid compounds of (9β-H)-pimarane nucleus with anti-colon cancer activity and derivatives thereof and preparation method thereof Technical Field
[0001] The present invention belongs to the field of medicine, and in particular relates to a (9β-H)-pimarane nucleus derivative with anti-colon cancer activity, and a preparation method and application thereof. Background Art
[0002] Colorectal cancer is the third most common malignant tumor, after lung cancer and stomach cancer. Its incidence ranks third among malignant tumors in men and second among malignant tumors in women. The incidence of colon cancer has increased particularly significantly. Colon cancer is one of the most significant health risks worldwide, characterized by high incidence, high recurrence, poor prognosis, and high mortality.
[0003] Common treatments for colon cancer include surgical resection, radiotherapy, chemotherapy, immunotherapy, and molecularly targeted therapy. Surgical resection is primarily indicated for patients with early-stage, localized metastases, such as stage I colon cancer. Stages II and III colon cancer are treated with a combination of surgery and chemotherapy, while advanced colon cancer is primarily treated with chemotherapy. Consequently, chemotherapy plays a crucial role in the treatment of colon cancer at all stages and has become the mainstay of treatment. Fluorouracil (5-FU), oxaliplatin, and irinotecan are commonly used chemotherapy drugs in the clinical treatment of colon cancer. 5-FU, a cornerstone drug for colon cancer, has been a key chemotherapy drug for over 40 years, demonstrating remarkable efficacy and a broad spectrum of anticancer activity. However, 5-FU can cause significant toxic side effects and potentially difficult-to-reverse drug resistance. Given the significant toxicity and side effects of 5-FU and other colon cancer chemotherapy drugs, which impact patients' quality of life, the discovery of new anticancer drugs with improved efficacy and minimal toxicity is urgently needed. Therefore, it is of great significance to isolate and screen non-toxic or low-toxic natural anti-tumor active ingredients from plants.
[0004] Icacina oliviformis (Poir.) J. Raynal is a drought-resistant perennial shrub of the genus Icacina in the family Cornaceae, primarily found in central and western Africa. The tubers of Icacina oliviformis are rich in starch and can be used as food during famines. The plant also has extensive medicinal value. Local people use its tubers as a medicine for various ailments, such as poisoning, constipation, and malaria. Alcohol-infused extracts of the tubers are also used as a first-aid remedy for emergencies such as food poisoning. Modern pharmacological studies have shown that Icacina oliviformis exhibits a variety of activities, including antitumor, anticonvulsant, sedative, analgesic, hypoglycemic, antibacterial, and seed germination inhibitory activities. Currently, research on Icacina oliviformis has primarily focused on its tubers, while research on the chemical composition of its leaves is lacking. Furthermore, compared to the tubers, the leaves have a strong regenerative capacity and are abundant, making them an environmentally friendly natural resource.
[0005] Summary of the Invention
[0006] The present invention aims to conduct in-depth research on the active ingredients in the leaves of I. oliviformis. Two new 3,4-seco-17-nor-pimarane-type compounds were isolated from the dried leaves of the plant and named secoicacinlivitholide F(1) and secoicacinlivitholide G(2). Another object of the present invention is to identify a method for preparing these new scaffold compounds.
[0007] Activity evaluations conducted in the present invention revealed that the compounds secoicacinlivitholide F and secoicacinlivitholide G exhibited certain anti-colon cancer cell proliferation activity. In particular, secoicacinlivitholide G exhibited significant anti-proliferative effects against both HT-29 and SW620 colon cancer cell lines, with both effects being more potent than the active agent 5-FU. Furthermore, the inhibitory effect of secoicacinlivitholide G on the HT-29 colon cancer cell line was approximately three times that of the active agent 5-FU. Secoicacinlivitholide G can be used to prepare anti-colon cancer drugs or as a lead compound for the development of anti-colon cancer drugs.
[0008] The present invention provides the following technical solution: a derivative of a (9β-H)-pimarane nucleus with anti-colon cancer activity, comprising a compound of the following general structural formula:
[0009] Wherein, R1 and R2 can both be hydrogen, acyl, saccharide, alkyl, cycloalkyl, alkylaryl, aryl, arylalkyl, arylalkenyl, arylalkynyl, or heterocyclic group.
[0010] As a preferred embodiment, the (9β-H)-pimarane diterpene described above is characterized in that R1 and R2 are hydrogen or alkyl.
[0011] As a more preferred embodiment, R1 is hydrogen or methyl, and R2 is hydrogen, selected from the following compounds:
[0012] The method for preparing two novel (9β-H)-pimarane diterpenoid skeleton compounds having anti-colon cancer activity according to the present invention is characterized by comprising the following steps:
[0013] (1) Weigh the dried I. oliviformis leaves, crush them, and soak them in ethanol or methanol aqueous solution at room temperature. Filter and collect the filtrate, and concentrate under reduced pressure until there is no alcohol smell to obtain a concentrate;
[0014] (2) extracting the concentrated solution obtained in step (1) with petroleum ether, ethyl acetate and n-butanol, respectively, and concentrating under reduced pressure to obtain a petroleum ether fraction, an ethyl acetate fraction and an n-butanol fraction;
[0015] (3) subjecting the n-butanol fraction obtained in step (2) to MCI reverse phase medium pressure preparative chromatography and eluting with a mixed solvent of methanol and water in different volume ratios;
[0016] (4) The eluate fraction Bu-1 obtained in step (3) at 47.00–55.00 min was subjected to MCI reverse phase medium pressure preparative gradient elution, and the effluent Bu-1-7 at 55.00–65.00 min was collected; the fraction Bu-1-7 was subjected to preparative high performance liquid chromatography to obtain secoicacinlivitholide F(1).
[0017] (5) The 55.00–63.00 min eluate fraction Bu-2 obtained in step (3) was subjected to MCI reverse phase medium pressure preparative gradient elution, and the 65.00–74.00 min eluate Bu-2-10 was collected; the fraction Bu-2-10 was subjected to preparative high performance liquid chromatography to obtain secoicacinlivitholide G (2).
[0018] As a preferred embodiment, the preparation method of the present invention comprises the following steps:
[0019] (1) Weigh 1.3 kg of dried I. oliviformis leaves, crush them, and add 13 L of 95% ethanol to soak the leaves at room temperature. Soak the leaves three times for 12 hours each time. Filter the filtrate, collect it, and concentrate it under reduced pressure until it is free of alcohol to obtain an extract.
[0020] (2) The drug solution obtained in step (1) is made into a suspension with an appropriate amount of water, and then extracted with equal volumes of petroleum ether, ethyl acetate and n-butanol, each extracted 4 times, to obtain a petroleum ether fraction, an ethyl acetate fraction, an n-butanol fraction and a raffinate fraction, respectively.
[0021] (3) The n-butanol fraction obtained in step (2) was mixed with sample and MCI at a ratio of 1:1.2, and gradient eluted using a medium pressure preparative MCI column chromatography (MCI particle size: 75–150 μm, 3.0 cm × 60.0 cm, column volume: 400 mL) with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–90.00 min, 55%-55% B; 90.00–110.00 min, 65%-65% B; 110.00–130.00 min, 75%-75% B; 130.00–160.00 min, 75%-100% B. The elution rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. After HPLC analysis, the resulting products were concentrated and combined using a rotary evaporator to obtain four fractions, Bu-1 to Bu-4.
[0022] (4) The eluate fraction Bu-1 obtained in step (3) at 47.00–55.00 min was subjected to MCI reverse phase medium pressure preparative gradient elution with methanol-water as the mobile phase, wherein A was pure water and B was methanol; the elution gradient was as follows: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–120.00 min, 45%-95% B. The elution flow rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. The effluent Bu-1-7 was collected between 55.00 and 65.00 min. Fraction Bu-1-7 was subjected to preparative HPLC using a mobile phase of pure water (A) and acetonitrile (B) (CH3CN-H2O, v / v, 41:59) as isocratic elution. A stock solution of compound 1 was collected between 53 and 57 min. The stock solution of compound 1 was then subjected to preparative HPLC to obtain the monomeric compound secoicacinlivitholide F. The column pressure was 9.8 MPa, the column temperature was 22-26°C, the mobile phase was pure water and acetonitrile in a 60:40 volume ratio, the injection volume was 100 μL, the flow rate was 3 mL / min, and the detection wavelength was 250 nm.
[0023] (5) The eluate fraction Bu-2 obtained in step (3) at 55.00–63.00 min was subjected to MCI reverse phase medium pressure preparative gradient elution with methanol-water as the mobile phase, wherein A is pure water and B is methanol; the elution gradient is as follows: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–90.00 min, 55%-55% B; 90.00–130.00 min, 55%-95% B. The elution flow rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. The effluent Bu-2-10 at 65.00–74.00 min was collected; fraction Bu-2-10 was subjected to preparative high performance liquid chromatography (HPLC) using pure water (A)-acetonitrile (B) as the mobile phase (CH3CN-H2O, v / v, 40:60) to isocratically elute, and a stock solution of compound 2 was collected at 50-54 min; the stock solution was further subjected to preparative high performance liquid chromatography to obtain the monomer compound secoicacinlivitholide G.
[0024] The activity experiment used a proliferation inhibition experiment on HT-29 colon cancer cells, and selected clinical 5-FU as the positive control drug. The MTT method was used to test the IC value of the compound on HT-29 colon cancer cells. 50 (half-maximal inhibitory concentration), ultimately proving that the above two compounds have good anti-colon cancer effects. The use of the above compounds in the preparation of anti-colon cancer drugs. Beneficial effects:
[0025] The present invention discovers two new 3,4-seco-17-nor-pimarane-type skeleton compounds, secoicacinlivitholide F and secoicacinlivitholide G, from the West African plant I. oliviformis, and provides extraction and separation technology, structure identification method and use of the compounds in inhibiting colon cancer cell proliferation. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Compound 1 1 H NMR spectrum (500 MHz, Methanol-d4).
[0027] Figure 2 Compound 1 13 C NMR spectrum (125 MHz, Methanol-d4).
[0028] Figure 3 DEPT 135 spectrum of compound 1 (125 MHz, Methanol-d4).
[0029] Figure 4 Compound 1 1 H- 1 H COSY diagram (500MHz, Methanol-d4).
[0030] Figure 5 HSQC diagram of compound 1 ( 1 H:500MHz, 13 C:125MHz).
[0031] Figure 6 HMBC diagram of compound 1 ( 1 H:500MHz, 13 C:125MHz).
[0032] Figure 7 NOSEY pattern of compound 1 (500 MHz, Methanol-d4).
[0033] Figure 8 Mass spectrum of compound 1.
[0034] Figure 9 UV spectrum of compound 1.
[0035] Figure 10 Compound 2 1H NMR spectrum (500 MHz, Methanol-d4).
[0036] Figure 11 Compound 2 13 C NMR spectrum (125 MHz, Methanol-d4).
[0037] FIG12 DEPT 135 spectrum of compound 2 (125 MHz, Methanol-d4).
[0038] Figure 13 Compound 2 1 H- 1 H COSY diagram (500MHz, Methanol-d4).
[0039] Figure 14 HSQC diagram of compound 2 ( 1 H:500MHz, 13 C:125MHz).
[0040] Figure 15 HMBC diagram of compound 2 ( 1 H:500MHz, 13 C:125MHz).
[0041] FIG16 NOSEY pattern of compound 2 (500 MHz, Methanol-d4).
[0042] Figure 17 Mass spectrum of compound 2.
[0043] Figure 18 UV spectrum of compound 2. DETAILED DESCRIPTION
[0044] Example 1
[0045] 1. Instruments and Materials
[0046] 1.1 Instrument
[0047] Experimental Materials
[0048] Hedera ODS preparative chromatography column (10 nm, 5 μm, 10 × 250 mm); Waters ACQUITY UPLC BEH C 18 (2.1 mm × 100 mm, 1.7 μm) chromatographic column; MCI GEL (CHP20, 75-150 μm), Sephadex LH-20 gel, column chromatography silica gel (200-300 mesh); chromatographic grade acetonitrile, methanol, and formic acid were purchased from Merck, USA; analytical grade petroleum ether, ethyl acetate, etc. were purchased from Nanjing Wanqing Chemical Reagent Co., Ltd.
[0049] 2. The preparation method of the compound is carried out according to the following steps:
[0050] (1) Weigh 1.3 kg of dried I. oliviformis leaves, crush them, add 13 L of 95% ethanol by volume, and soak the leaves at room temperature for three times, each time for 12 hours. Filter and collect the filtrate, and concentrate under reduced pressure until there is no alcohol taste to obtain an extract.
[0051] (2) The extract obtained in step (1) was made into a suspension with 1000 mL of water, and then extracted with equal volumes of petroleum ether, ethyl acetate and n-butanol, each extracted 4 times, to obtain a petroleum ether fraction, an ethyl acetate fraction, an n-butanol fraction and a raffinate fraction, respectively.
[0052] (3) The n-butanol fraction obtained in step (2) was mixed with sample and MCI at a ratio of 1:1.2, and gradient eluted using a medium pressure preparative MCI column chromatography (MCI particle size: 75–150 μm, 3.0 cm × 60.0 cm, column volume: 400 mL) with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–90.00 min, 55%-55% B; 90.00–110.00 min, 65%-65% B; 110.00–130.00 min, 75%-75% B; 130.00–160.00 min, 75%-100% B. The elution rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. After HPLC analysis, the resulting products were concentrated and combined using a rotary evaporator to obtain four fractions, Bu-1 to Bu-4.
[0053] (4) Fraction Bu-1 obtained in step (3) was subjected to gradient elution using a medium pressure preparative MCI column chromatography (MCI particle size: 75–150 μm, 3.0 cm × 60.0 cm, column volume: 400 mL) with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–120.00 min, 45%-95% B. The elution flow rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. After analysis by high performance liquid chromatography, the residues were concentrated and combined using a rotary evaporator to obtain 13 fractions Bu-1-1 to Bu-1-13.
[0054] (5) The fraction Bu-1-7 obtained in step (4) was subjected to reverse phase C 18 Purification was performed by preparative HPLC (Hedera ODS, 5μm, 2.1×250mm). The mobile phase was isocratic elution (CH3CN-H2O, v / v, 41:59) using pure water (A) and acetonitrile (B). Detection wavelengths were 250 nm and 310 nm, at a flow rate of 3 mL / min and a column temperature of 30°C. A stock solution of compound 1 was collected between 53 and 57 min. This stock solution of compound 1 was then subjected to preparative HPLC to obtain monomeric compound 1 (2.6 mg). The HPLC column pressure was 9.8 MPa, the chromatographic column was Hedera ODS, the column temperature was 22-26°C, the mobile phase was pure water and acetonitrile in a volume ratio of 60:40, the injection volume was 100 μL, the flow rate was 3 mL / min, and the detection wavelength was 250 nm.
[0055] (6) Fraction Bu-2 obtained in step (3) was subjected to gradient elution using a medium pressure preparative MCI column chromatography (MCI particle size: 75–150 μm, 3.0 cm × 60.0 cm, column volume: 400 mL) with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01–10.00 min, 5%-5% B; 10.00–20.00 min, 15%-15% B; 20.00–30.00 min, 25%-25% B; 30.00–50.00 min, 35%-35% B; 50.00–70.00 min, 45%-45% B; 70.00–90.00 min, 55%-55% B; 90.00–130.00 min, 55%-95% B. The elution flow rate was 20 mL / min, and the detection wavelengths were 250 nm and 310 nm. After analysis by high performance liquid chromatography, the residues were concentrated and combined using a rotary evaporator to obtain 11 fractions Bu-2-1 to Bu-2-11.
[0056] (7) The fraction Bu-2-10 obtained in step (6) was subjected to reverse phase C 18 Purification was performed by preparative HPLC (Hedera ODS, 5μm, 1.5×250mm). The mobile phase was isocratic elution (CH3CN-H2O, v / v, 40:60) using pure water (A) and acetonitrile (B). The detection wavelengths were 250 nm and 310 nm, the flow rate was 3 mL / min, and the column temperature was 30°C. A stock solution of compound 2 was collected between 50 and 54 minutes. The stock solution of compound 2 was then subjected to preparative HPLC to obtain monomeric compound 2 (4.41 mg). The HPLC column pressure was 9.8 MPa, the chromatographic column was Hedera ODS, the column temperature was 22-26°C, the mobile phase was pure water-acetonitrile (60:40 by volume), the injection volume was 80 μL, the flow rate was 3 mL / min, and the detection wavelength was 250 nm.
[0057] 3. Structural analysis of the compound:
[0058] 3.1 Structural identification of Secoicacinlivitholide F(1)
[0059] Compound 1 is a white powder. (c 0.01, MeOH), combined 13 C NMR data and high-resolution mass spectrometry (HRESIMS) gave a quasi-molecular ion peak at m / z 363.1426 ([M+H] + , C 19 H 23 O7 +The calculated value is: 363.1444), and the molecular formula of the compound can be deduced to be C 19 H 22 O7, the degree of unsaturation is 9. The hydrogen spectrum of compound 1 (Table 1) shows a signal of 1 methyl proton δ H (1.29, d, CH3-18) and two olefin proton signals δ H (6.67,d,H-15; 7.54,d,H-16). 13 CNMR spectrum and DEPT spectrum showed that the compound had 19 carbon signals, including 1 methyl carbon, 5 methylene carbons (including 1 oxymethylene), 7 methine carbons (including 1 oxymethylene), 3 quaternary carbons (including 1 quaternary carbon) and 3 carbonyl carbons. 1 H and 13 C NMR data, in compound 1, there are two methylene δ C (30.7, C-1; 26.8, C-2), 1 carboxyl group δ C (177.0, C-3), 2 methine δ C (38.7, C-4; 46.9, C-5) and 1 quaternary carbon δ C (50.8, C-10). The above evidence indicates that in compound 1, ring opening occurs between C-3 and C-4. In addition, the HMBC spectrum shows that H2-20 and C-6 (δ C 77.6), indicating the presence of a 6,20-epoxy bridge. The planar structure of compound 1 is represented by 1 H- 1 The results were further confirmed by H COSY, HSQC and HMBC spectra.
[0060] The relative configuration of compound 1 was determined by analyzing the NOESY spectrum (Figure 7). To date, the diterpenoids isolated from the genus Cornus are all (9β-H)-pimarane and its derivatives. Therefore, H-5 in compound 1 is determined to be α-oriented. In the NOESY spectrum, H-5 (δ H 2.48) and H-6(δ H 4.46), CH3-18(δ H 1.29), indicating that H-5 / H-6 / CH3-18 are all α-oriented. H 2.54) and H-20β(δ H 3.83) related, H-20α(δ H 4.02) and H-8(δ H 3.48) and H-9 (δ H2.65) correlation, indicating that H-8 / H-9 / H2-20 are all β-oriented. Therefore, the structure of compound 1 was determined and named secoicacinlivitholide F. Compound 1 is the first naturally discovered new 3,4-seco-17-nor-pimarane skeleton compound with a 6,20-epoxy bridge.
[0061] 3.2 Structural identification of Secoicacinlivitholide G(2)
[0062] Compound 2 is a white powder. (c 0.02, MeOH), combined 13 C-NMR data and high-resolution mass spectrometry (HRESIMS) gave a quasi-molecular ion peak at m / z 377.1607 ([M+H] + , C 20 H 25 O7 + The calculated value is: 377.1600), and the molecular formula of the compound can be deduced to be C 20 H 24 O7, unsaturation is 9. Comparison of compounds 2 and 1 1 H-NMR and 13 C-NMR spectrum shows that compound 2 has one more methoxy group than compound 1. HMBC spectrum shows OCH3(δ H 3.64,δ C 52.2) and C-3(δ C 175.2), indicating that the methoxy group is connected to C-3. Therefore, it can be determined that compound 2 is a 3-methoxy derivative of compound 1. The planar structure of compound 2 is shown in FIG. 1 H- 1 The structure of compound 2 was confirmed by H COSY, HSQC and HMBC spectra, and the compound was named as secoicacinlivitholide G. The relative configuration of compound 2 was the same as that of compound 1.
[0063] Table 1. Compounds 1 and 2 1 H and 13 C NMR data ( 1 H, 500MHz; 13 C,125MHz)
[0064] Example 2
[0065] The anti-colon cancer activity test study of the present invention is carried out according to the following steps:
[0066] 1. Tumor Cell Culture
[0067] Colon cancer cell lines HT-29 and SW620 (Cell Bank, Chinese Academy of Sciences) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, USA) at 37°C and 5% CO2. For subculture, a plate of tumor cells was removed, the culture medium removed, and washed twice with 3 mL of PBS. The cells were then digested with 1 mL of trypsin for 2 minutes, followed by 1 mL of culture medium to terminate digestion. The cells were then centrifuged at room temperature for 5 minutes at 1000 rpm. The supernatant was removed, and the cell suspension was resuspended in 1 mL of DMEM supplemented with 10% fetal bovine serum.
[0068] 2. Preparation of Experimental Drugs
[0069] Appropriate amounts of Compounds 1 and 2 prepared in Example 1 were weighed and dissolved in DMSO to a final concentration of 4 mM. The stock solutions were stored at 4°C. Prior to the experiment, the stock solutions were diluted with DMEM medium to a drug concentration of 20 μM, ensuring that the final DMSO concentration was less than 0.1%. Different volumes of DMEM medium were added to dilute the compounds to different concentrations. DMEM medium containing 0.1% DMSO was also used as a negative control.
[0070] 3. Drug toxicity to tumor cell lines
[0071] Tumor cells were suspended in culture medium at a density of 6 × 10 3 The cells were inoculated into 96-well plates (100 μL / well) and cultured at 37° C. under 5% CO 2 for 24 h. During the logarithmic growth phase of the tumor cell lines, different concentrations of compounds were added and cultured at 37° C. under 5% CO 2 for 24 h.
[0072] 4. MTT assay to detect cell viability
[0073] After the drug interacted with the tumor cells for 24 hours, 20 μL of MTT solution (5 mg / mL) was added to each well and incubated in a sterile incubator for 3 hours. The supernatant was completely aspirated and 150 μL of DMSO was added to each well. The cells were shaken for 30 minutes to dissolve the blue-purple formazan crystals. The OD value was measured at a wavelength of 570 nm using a microplate reader. The IC value of the compound was calculated using GraphPad Prism 8 software. 50 (half inhibitory concentration), and 5-FU was used as a positive control.
[0074] 5. The experimental results are shown in Table 2:
[0075] Table 2. Inhibitory effects of compounds 1 and 2 on colon cancer cell lines (IC 50 :μM)
[0076] Experimental Conclusion: Evaluation of the anti-colon cancer cell activity of compounds 1 and 2 revealed that compound 2 exhibited significant anti-proliferative effects against both HT-29 and SW620 colon cancer cell lines, with both effects being more potent than the active agent 5-FU. Compound 2 exhibited approximately three times the inhibitory effect on the HT-29 colon cancer cell line compared to the active agent 5-FU, suggesting its potential for development as a new anti-colon cancer drug.
Claims
1. A diterpenoid compound of the (9β-H)-pimarane nucleus with anti-colon cancer activity and its derivatives, characterized in that: It includes compounds with the following general structural formula: Wherein, R1 and R2 can both be hydrogen, acyl, saccharide, alkyl, cycloalkyl, alkylaryl, aryl, arylalkyl, arylalkenyl, arylalkynyl, or heterocyclic group.
2. The diterpenoid compound of the (9β-H)-pimarane nucleus and its derivatives having anti-colon cancer activity according to claim 1, characterized in that: R1 and R2 are hydrogen or alkyl.
3. The diterpenoid compound of the (9β-H)-pimarane nucleus and its derivatives having anti-colon cancer activity according to claim 2, characterized in that: R1 is hydrogen or methyl, and R2 is hydrogen.
4. A method for preparing a diterpenoid compound of a (9β-H)-pimarane nucleus having anti-colon cancer activity and its derivatives, characterized in that: The following steps are involved: (1) Weigh the dried I. oliviformis leaves, crush them, add ethanol or methanol aqueous solution to soak the medicinal materials at room temperature, collect the filtrate after filtering, and concentrate it under reduced pressure until there is no alcohol taste to obtain a concentrated solution; (2) extracting the concentrated solution obtained in step (1) with petroleum ether, ethyl acetate and n-butanol respectively, and concentrating under reduced pressure to obtain a petroleum ether fraction, an ethyl acetate fraction and an n-butanol fraction; (3) separating the n-butanol fraction obtained in step (2) by MCI reverse phase medium pressure preparative chromatography and eluting with a mixed solvent of methanol and water in different volume ratios; (4) subjecting the eluate fraction Bu-1 obtained in step (3) at 47.00-55.00 min to MCI reverse phase medium pressure preparative gradient elution, collecting the effluent Bu-1-7 at 55.00-65.00 min; subjecting the fraction Bu-1-7 to preparative high performance liquid chromatography to obtain compound 1, i.e., secoicacinlivitholide F; (5) The eluate fraction Bu-2 obtained in step (3) at 55.00-63.00 min was subjected to MCI reverse phase medium pressure preparative gradient elution, and the effluent Bu-2-10 at 65.00-74.00 min was collected; the fraction Bu-2-10 was further subjected to preparative high performance liquid chromatography to obtain compound 2, i.e., secoicacinlivitholide G.
5. The method for preparing the diterpenoid compounds and derivatives thereof of the (9β-H)-pimarane nucleus having anti-colon cancer activity according to claim 4, characterized in that: The following steps are involved: (1) Weigh 1.3 kg of dried I. oliviformis leaves, crush them, add 13 L of 95% ethanol and soak them at room temperature for three times, each time for 12 hours, filter and collect the filtrate, and concentrate under reduced pressure until there is no alcohol taste to obtain an extract; (2) the extract obtained in step (1) is made into a suspension with an appropriate amount of water, and then extracted with equal volumes of petroleum ether, ethyl acetate and n-butanol for 4 times, respectively, to obtain a petroleum ether fraction, an ethyl acetate fraction, an n-butanol fraction and a raffinate fraction; (3) The n-butanol fraction obtained in step (2) was mixed with sample:MCI=1:1.2, and gradient eluted by medium pressure preparative-MCI column chromatography, with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01-10.00min, 5%-5%B; 10.00-20.00min, 15%-15%B; 20.00-30.00min, 25%-25%B; 30.00-50.00min, 35%-35%B; 50.00-70.00min, 45%-45%B; 70.00-90.00min, 55%-55%B; 90.00-110.00min, 65%-65%B; 110.00-130.00min, 75%-75%B; 130.00-160.00min, 75%-100%B; elution flow rate 20mL / min, detection wavelengths 250nm and 310nm; after HPLC analysis, concentrated and combined to obtain 4 fractions Bu-1 to Bu-4; (4) The 47.00-55.00 min eluate fraction Bu-1 obtained in step (3) was subjected to MCI reverse phase medium pressure preparative gradient elution with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01-10.00 min, 5%-5% B; 10.00-20.00min, 15%-15% B; 20.00-30.00min, 25%-25% B; 30.00-50.00min, 35%-35% B; 50.00-70.00min, 45%-45% B; 70.00-120.00min, 45%-95% B; elution flow rate 20mL / min, detection wavelengths of 250nm and 310nm; collect effluent Bu-1-7 from 55.00-65.00min; fraction Bu-1-7 was subjected to preparative high performance liquid chromatography, eluted isocratically with pure water A and acetonitrile B in a volume ratio of 59:41 as the mobile phase, and the stock solution of compound 1 was collected in the time period of 53-57min; the stock solution of compound 1 was purified by preparative high performance liquid chromatography to obtain the monomer compound secoicacinlivitholide F; (5) The 55.00-63.00 min eluate fraction Bu-2 obtained in step (3) was subjected to MCI reverse phase medium pressure preparative gradient elution, with methanol-water as the mobile phase, wherein A is pure water and B is methanol; elution gradient: 0.01-10.00 min, 5%-5% B; 10.00-20.00 min, 15%-15% B; 20.00-30.00 min, 25%-25% B; 30.00-50.00 min, 35%-35% B; 50.00-70.00 min, 45%-45% B; 70.00-90.00 min , 55%-55% B; 90.00-130.00min, 55%-95% B; elution flow rate 20mL / min, detection wavelengths 250nm and 310nm; collect the effluent Bu-2-10 at 65.00-74.00min; subject the fraction Bu-2-10 to preparative high performance liquid chromatography, isocratically eluted with pure water A-acetonitrile B in a volume ratio of 60:40 as the mobile phase, and collect the stock solution of compound 2 in the time period of 50-54min; the stock solution of compound 2 is further purified by preparative high performance liquid chromatography to obtain the monomer compound secoicacinlivitholide G.
6. The method for preparing diterpenoid compounds and derivatives thereof of the (9β-H)-pimarane nucleus having anti-colon cancer activity according to claim 5, characterized in that: The preparative high performance liquid chromatography described in step (4) has a column pressure of 9.8 MPa, a column temperature of 22-26° C., a mobile phase of pure water-acetonitrile in a volume ratio of 60:40, an injection volume of 100 μL, a flow rate of 3 mL / min, and a detection wavelength of 250 nm.
7. The method for preparing the diterpenoid compounds and derivatives thereof of the (9β-H)-pimarane nucleus having anti-colon cancer activity according to claim 5, characterized in that: The preparative high performance liquid chromatography described in step (5) has a column pressure of 9.8 MPa, a column temperature of 22-26° C., a mobile phase of pure water-acetonitrile in a volume ratio of 60:40, an injection volume of 80 μL, a flow rate of 3 mL / min, and a detection wavelength of 250 nm.
8. Use of the diterpenoid compounds of the (9β-H)-pimarane core and their derivatives as claimed in any one of claims 1 to 3 in the preparation of anti-digestive tract cancer drugs.
9. Use of the diterpenoid compounds of the (9β-H)-pimarane nucleus and derivatives thereof according to any one of claims 1 to 3 in the preparation of anti-colon cancer drugs.
10. A pharmaceutical composition comprising the diterpenoid compound of the (9β-H)-pimarane core and its derivatives as claimed in any one of claims 1 to 3 and pharmaceutically acceptable excipients.
Citation Information
Patent Citations
New daphnane diterpene compounds in Daphne genkwa as well as preparation method and application of same
CN101531644A
Pimarane diterpene compounds containing four-membered rings and antitumor application thereof
CN108264462A
A pimarane type diterpenoid compound having an oxygen-containing five-membered ring, a preparation method and application thereof
CN108570025A
Bitter lignin compound with anti-tumor activity as well as preparation method and application thereof
CN114409670A
(9beta-H)-pimarane mother nucleus diterpenoid compound with anti-colon cancer activity and derivative and preparation method of (9beta-H)-pimarane mother nucleus diterpenoid compound
CN116606302A
